MOESM1 of Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso

Additional file 1: Table S1. Risk factors associated with the Pfdhfr C59R mutation. The data provided showed the association between time between last SP dose and the survey and the prevalence of Pfdhfr C59R mutation using a logistic regression model adjusted for residence, age, and gravidity

Non-inferiority plots for primary outcomes and mean birth weight.

<p>The figures show two-sided 90%, 95% and 99% confidence intervals (largest to smallest vertical bars, respectively), equivalent to one-sided 95%, 97.5% and 99.5% confidence intervals. The dashed blue vertical line indicates the non-inferiority margin. ATP, according to protocol population (adjusted for site); adjusted, ATP population adjusted for site, gravidity, age group, gestational age, ITN use and socio-economic status; ITT, intention to treat, (adjusted for site). Numbers included in the analyses and numeric values of the estimates are provided in the supplement (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132247#pone.0132247.s012" target="_blank">S4 Table</a>).</p

Baseline characteristics of the study participants.

<p>CI; Confidence interval; IRS, indoor residual spraying of insecticide; IQR, inter-quartile range; SD, standard deviation.</p><p>Baseline characteristics of the study participants.</p

Distribution of birth weight (A) and hemoglobin concentration (B) at fourth ANC visit by intervention group.

<p>Birth weight distributions were estimated using data from 2183 women in the IPTp-SP group and from 2208 women in the ISTp-AL group. Hemoglobin distributions utilise data from 1534 women in the IPTp-SP group and from 1600 women in the ISTp-AL group.</p

Risk of low birth weight and anemia by intervention group.

<p>CI; Confidence interval. Numbers shown are for the according to protocol (ATP) population. The odds ratio is given as the measure of effect because the non-inferiority margin for the OR (1.263 for low birth weight) can be defined independently of the underlying prevalence. The pooled estimate of the odds ratio is also not affected by changes in prevalence in the different sites as the risk difference or risk ratio would be. Outcomes for low birth weight split by gravidity are given in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132247#pone.0132247.s013" target="_blank">S5 Table</a>.</p><p>Risk of low birth weight and anemia by intervention group.</p

Adverse birth outcomes and deaths.

<p>CI; Confidence interval.</p><p>¹ Details of the congenital abnormalities are given in the supplement, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132247#pone.0132247.s018" target="_blank">S10 Table</a>. Small for gestational age was defined as birth weight less than the 10th centile of the nomogram defined by Landis et al.[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132247#pone.0132247.ref028" target="_blank">28</a>]</p><p>Adverse birth outcomes and deaths.</p